NASDAQ: IMNM · Life Sciences · 3 alerts · CIK 1472012
Share price
$17.61Close, Nov 16
Market cap
$2.08B
Shares outstanding
118.07MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Immunome Inc. filings on SEC EDGAR ↗
Immunome Inc. reported a net loss of $212.4 million for 2025, an improvement from $293.0 million in 2024, primarily due to a significant decrease in in-process research and development expenses. The company significantly strengthened its liquidity position, ending 2025 with $653.5 million in cash and cash equivalents following two major public offerings that raised over $594 million in net proceeds.
Immunome reported third quarter 2026 financial results and provided a pipeline update, highlighting an FDA PDUFA date of April 28, 2027, for varegacestat. The company also announced IND clearance for its solid tumor ADC candidate IM-1340 and plans to initiate a Phase 1 trial by year-end 2026.
Term
Q3 2026
“We made significant progress across our oncology pipeline in recent months. We continue to advance varegacestat toward approval and launch, with an FDA PDUFA date of April 28, 2027, and recent EMA validation of our MAA. Beyond varegacestat, we now have three programs in the clinic, with IM-1340 expected to become the fourth by year-end. We are progressing the Phase 1 study of IM-1021, our ROR1-targeted ADC, and look forward to presenting updated Phase 1 data at ASH in December.”
Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome
Immunome entered into an amendment with Bristol-Myers Squibb (BMS) to eliminate all future milestone and royalty payment obligations related to varegacestat and AL101. In exchange, Immunome paid BMS $20 million in cash and issued approximately 4.4 million shares of common stock, while also gaining full ownership of the related patent rights.